Combining miR-10b–Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer

Byunghee Yoo(Athinoula A. Martinos Center for Biomedical Imaging), Zdravka Medarova(Io Therapeutics (United States)), Pamela Pantazopoulos(Athinoula A. Martinos Center for Biomedical Imaging), Kornélia Polyák(Dana-Farber Cancer Institute), Victoria Petkova(Beth Israel Deaconess Medical Center), Anna Moore(Athinoula A. Martinos Center for Biomedical Imaging), Doris P. Tabassum(Dana-Farber Cancer Institute), Aseda Tena(Massachusetts General Hospital), Alana Ross(Athinoula A. Martinos Center for Biomedical Imaging), Amol Kavishwar(Athinoula A. Martinos Center for Biomedical Imaging), Ping Wang(Xi'an Polytechnic University), Natalia Barteneva(Boston Children's Hospital)
Cancer Research
September 11, 2015
10.1158/0008-5472.can-15-0888
Cited by 76

Related Papers

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
|Cell|2008|8.7k
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
|Nature reviews. Cancer|2009|3.3k
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
|Nature|2007|3.2k
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
A model for p53-induced apoptosis
|Nature|1997|2.5k